Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

NCT ID: NCT03796390

Last Updated: 2019-01-11

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-26
• Study Completion Date: 2021-06-06

Brief Summary

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia. A total of 15 patients are planned to be enrolled following up one year.

Detailed Description

Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be potential in developing the corresponding CAR-T cells to treat patients whose tumors expressing those markers. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with Acute Myelocytic Leukemia. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.

Conditions

Acute Myelocytic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CD123 CAR-T cells

Patients will be be treated with CD123 CAR-T cells

Group Type: EXPERIMENTAL

CD123 CAR-T cells

Intervention Type: BIOLOGICAL

Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.

Interventions

CD123 CAR-T cells

Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Subjects with acute myeloid leukemia who voluntarily signed informed consent and met the following criteria:

1. Diagnosed as recurrent or refractory acute myeloid leukemia

2. Tumor cells confirmed CD123 positive by Flow cytometry (FCM) or immunohistochemical detection, and CD123 positive rate >80%

3. Age ≥ 2 years old, and <65 years old

4. Estimated survival time is longer than 3 months from the date of signing the informed consent form

5. KPS ≥ 80 points

6. Important organs function need to meet the following conditions:

1) EF>50%, and there is no obvious abnormality in ECG; 2) SpO2≥90%; 3)Cr≤2.5ULN; 4)ALT and AST≤4ULN, TBil≤50μmol/L 7. Subjects with a pregnancy plan must agree to take contraception before the enrollment study and after the study lasts for six months; if the subject is pregnant or suspects of pregnancy, the investigator should be notified immediately 8. Need to stop chemotherapy for at least 2 weeks before collecting the blood to manufacture CAR-T cells.

9. For allogeneic hematopoietic stem cell transplantation subjects, it is necessary to stop the immunosuppressant against GVHD for at least 2 weeks before collecting autologous blood preparation, and if the donor is preparing blood, it is of no influence; 10. If the subject has a history of central nervous system (CNS) leukemia, the tumor cells in the cerebrospinal fluid need to be cleared and the white blood cell count <5 * 10^6 / L ,then can proceed lymphodepletion 11. Subjects who participate in other studies must withdraw other studies for 2 weeks before they can be enrolled.

Exclusion Criteria

1. Combine other diseases not effectively controlled, including but not limited to persistent or poorly controlled infections, symptomatic congestive heart failure, unstable angina, arrhythmia, poorly controlled lung disease or mental illness

2. There are other active malignant tumors

3. Combined serious infection and can not be effectively controlled

4. Active hepatitis (HBV DNA or hepatitis C virus ribonucleic acid [HCVRNA] detection positive)

5. Human immunodeficiency virus (HIV) infection or syphilis infection

6. Have a history of severe allergies in biological products (including antibiotics)

7. One month after discontinuation of immunosuppressants, allogeneic hematopoietic stem cell transplantation patients still have acute graft versus host response (GvHD)

8. Female subjects are pregnant or lactating

9. Systemic administration of glucocorticoids within one week prior to CAR-T treatment

10. In the past, there was a prolonged QT interval or severe heart disease.

11. Active autoimmune diseases requiring systemic immunosuppressive therapy

12. The investigator believes that it may increase the risk of the subject or interfere with the study results.

Exit criteria：

1. The subjects request to withdraw from the study before CAR-T infusion

2. The subjects seriously violate the protocol

3. Before CAR-T infusion, the following indicators are still abnormal after treatment:

1) EF>50%, and there is no obvious abnormality in ECG 2) SpO2≥90% 3)Cr≤2.5ULN(the upper limit of normal ) 4) ALT and AST ≤ 4ULN, TBil ≤ 50μmol / L 4.Not enough T cells for manufacture standard CAR-T cells 5. Other serious adverse events occurred

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hebei Yanda Ludaopei Hospital

OTHER

Sponsor Role: collaborator

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peihua Lu, PhD&MD

Role: STUDY_CHAIR

Hebei Yanda Ludaopei Hospital

Locations

Hebei Yanda Ludaopei Hospital

Langfang, Hebei, China

Site Status: RECRUITING

Countries

China

Central Contacts

Peihua Lu, PhD&MD

Role: CONTACT

peihua_lu@126.com

008618611636172

Jianqiang Li, PhD&MD

Role: CONTACT

limmune@gmail.com

008615511369555

Facility Contacts

Peihua Lu, PhD&MD

Role: primary

peihua_lu@126.com

008618611636172

Other Identifiers

Daopei CD123CAR-T

Identifier Type: -

Identifier Source: org_study_id